Can Wegovy (semaglutide) affect irritability and anxiety?

Can Wegovy Affect Irritability and Anxiety?

Wegovy (semaglutide) is associated with anxiety as a reported adverse effect, but emerging evidence suggests it may actually reduce anxiety and depression symptoms rather than worsen them in most patients.

FDA-Approved Safety Profile

The FDA drug label for Wegovy explicitly lists anxiety as an adverse reaction occurring in 4% of pediatric patients (ages 12+) treated with Wegovy versus 2% of placebo-treated patients 1. This represents a documented increase in anxiety reporting in the clinical trial population. However, irritability is not specifically listed as a distinct adverse reaction in the FDA labeling 1.

Emerging Clinical Evidence Shows Protective Effects

Contrary to the pediatric trial findings, the most recent and highest quality evidence from a 2026 Swedish national cohort study of 95,490 patients with pre-existing depression or anxiety found that semaglutide was associated with significantly reduced risk of worsening mental illness 2. Specifically:

• 58% reduction in worsening mental illness (adjusted HR 0.58,95% CI 0.51-0.65)
• 44% reduction in worsening depression (aHR 0.56,95% CI 0.44-0.71)
• 38% reduction in worsening anxiety (aHR 0.62,95% CI 0.52-0.73)
• 44% reduction in self-harm (aHR 0.56,95% CI 0.34-0.92)

This real-world evidence from patients already diagnosed with anxiety disorders suggests semaglutide may be protective rather than harmful for mood and anxiety symptoms.

Pharmacovigilance Data Reveals Important Nuances

A 2025 multinational pharmacovigilance study analyzing over 2 million adverse drug reaction reports found significant signals for anxiety (aROR 1.26), depressed mood disorders (aROR 1.70), and suicidality (aROR 1.45) specifically with semaglutide 3. However, critically:

• These signals were not present in sensitivity analyses before June 2021 (before semaglutide's approval for weight management)
• The signals emerged primarily after approval for obesity treatment, suggesting potential reporting bias or population-specific effects
• No overall increase in psychiatric adverse reactions was found except for eating disorders and depression/suicidality

Mechanistic Evidence Supports Anxiolytic Effects

Multiple preclinical studies demonstrate semaglutide's potential to reduce anxiety through neurobiological mechanisms:

• Semaglutide reduced anxiety-like behaviors in diabetic mouse models through modulation of the microbiota-gut-brain axis, reducing hippocampal neuroinflammation and improving neurotransmitter systems 4
• Treatment improved anxiety indices in Alzheimer's disease models, showing potential anxiolytic effects 5
• Semaglutide reduced neuroinflammation and improved mood-related behaviors in diabetic mice through effects on the kynurenine pathway 6

Clinical Interpretation and Recommendations

For patients without pre-existing psychiatric conditions: The 4% incidence of anxiety in pediatric trials represents a modest increase that should be monitored, but the absolute risk remains low 1.

For patients with pre-existing anxiety or depression: The Swedish cohort data suggests semaglutide may actually be beneficial, with substantial reductions in worsening mental health outcomes 2. This represents the highest quality real-world evidence available.

Key monitoring considerations:

• Screen for baseline psychiatric symptoms before initiating treatment
• Monitor mood and anxiety symptoms during dose escalation (when most adverse effects occur)
• Be particularly vigilant in patients treated for obesity (rather than diabetes), as post-marketing surveillance suggests higher reporting rates in this population 3
• Consider that gastrointestinal side effects (nausea in 44%, vomiting in 25%) may indirectly contribute to irritability and mood changes 1

Important Caveats

The discrepancy between controlled trial data showing increased anxiety reporting and real-world evidence showing protective effects likely reflects:

1. Population differences: Patients with pre-existing mental health conditions may respond differently than those without
2. Indirect effects: Weight loss and metabolic improvements may improve mood, offsetting direct drug effects
3. Reporting bias: Increased media attention post-2021 may have amplified adverse event reporting

The balance of evidence, particularly the most recent large-scale cohort study, suggests that anxiety and irritability are not major concerns for most patients, and semaglutide may actually provide mental health benefits in those with pre-existing mood disorders 2.